Novavax Stock: Buy, Sell, or Hold in 2022?
Novavax (NASDAQ: NVAX) has taken investors on quite an exciting ride since it entered the coronavirus vaccine race. The biotech leaped into the spotlight in the early days of the pandemic when it won $1.6 billion in support from the U.S. government. And the company finished 2020 with a gain of more than 2,700%.
But the Novavax story became more complicated last year. Investors expected Novavax to apply for U.S. regulatory authorization in the first half. Instead, troubles with a manufacturing ramp up got in the way. The stock has dropped nearly 60% from highs reached in February of last year. Novavax has since resolved its production issues and today is on track to apply for U.S. authorization in about a month. Now the question is whether we should hang on to hopes and buy or hold the shares -- or whether we should sell. Let's take a closer look.
Image source: Getty Images.
Source Fool.com